Literature DB >> 19686238

Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons.

Nikita Rudinskiy1, Yoshio A Kaneko, Ayshe Ana Beesen, Ozgun Gokce, Etienne Régulier, Nicole Déglon, Ruth Luthi-Carter.   

Abstract

Hippocalcin is a neuronal calcium sensor protein previously implicated in regulating neuronal viability and plasticity. Hippocalcin is the most highly expressed neuronal calcium sensor in the medium spiny striatal output neurons that degenerate selectively in Huntington's disease (HD). We have previously shown that decreased hippocalcin expression occurs in parallel with the onset of disease phenotype in mouse models of HD. Here we show by in situ hybridization histochemistry that hippocalcin RNA is also diminished by 63% in human HD brain. These findings lead us to hypothesize that diminished hippocalcin expression might contribute to striatal neurodegeneration in HD. We tested this hypothesis by assessing whether restoration of hippocalcin expression would decrease striatal neurodegeneration in cellular models of HD comprising primary striatal neurons exposed to mutant huntingtin, the mitochondrial toxin 3-nitropropionic acid or an excitotoxic concentration of glutamate. Counter to our hypothesis, hippocalcin expression did not improve the survival of striatal neurons under these conditions. Likewise, expression of hippocalcin together with interactor proteins including the neuronal apoptosis inhibitory protein did not increase the survival of striatal cells in cellular models of HD. These results indicate that diminished hippocalcin expression does not contribute to HD-related neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19686238     DOI: 10.1111/j.1471-4159.2009.06344.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

1.  SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis.

Authors:  Ruth Luthi-Carter; David M Taylor; Judit Pallos; Emmanuel Lambert; Allison Amore; Alex Parker; Hilary Moffitt; Donna L Smith; Heike Runne; Ozgun Gokce; Alexandre Kuhn; Zhongmin Xiang; Michele M Maxwell; Steven A Reeves; Gillian P Bates; Christian Neri; Leslie M Thompson; J Lawrence Marsh; Aleksey G Kazantsev
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-08       Impact factor: 11.205

Review 2.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

3.  Synchrotron infrared microspectroscopy detecting the evolution of Huntington's disease neuropathology and suggesting unique correlates of dysfunction in white versus gray brain matter.

Authors:  Markus Bonda; Valérie Perrin; Bertrand Vileno; Heike Runne; Ariane Kretlow; László Forró; Ruth Luthi-Carter; Lisa M Miller; Sylvia Jeney
Journal:  Anal Chem       Date:  2011-09-22       Impact factor: 6.986

4.  Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

Authors:  Sara Valdeolivas; Carmen Navarrete; Irene Cantarero; María L Bellido; Eduardo Muñoz; Onintza Sagredo
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

5.  Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease.

Authors:  Bin Tang; Tamara Seredenina; Giovanni Coppola; Alexandre Kuhn; Daniel H Geschwind; Ruth Luthi-Carter; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2011-02-18       Impact factor: 5.996

6.  MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.

Authors:  David M Taylor; Roger Moser; Etienne Régulier; Lionel Breuillaud; Meredith Dixon; Ayshe Ana Beesen; Linda Elliston; Mariana de Fatima Silva Santos; Jinho Kim; Lesley Jones; Darlene R Goldstein; Robert J Ferrante; Ruth Luthi-Carter
Journal:  J Neurosci       Date:  2013-02-06       Impact factor: 6.167

7.  Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation.

Authors:  Tamara Seredenina; Ozgun Gokce; Ruth Luthi-Carter
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

8.  Proteomic analysis of the regenerating liver following 2/3 partial hepatectomy in rats.

Authors:  Xiao-Guang Chen; Cun-Shuan Xu
Journal:  Biol Res       Date:  2014-11-19       Impact factor: 5.612

9.  MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms.

Authors:  Ana Jovicic; Julien Francisco Zaldivar Jolissaint; Roger Moser; Mariana de Fatima Silva Santos; Ruth Luthi-Carter
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

Review 10.  Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's disease.

Authors:  Laetitia Francelle; Laurie Galvan; Emmanuel Brouillet
Journal:  Front Cell Neurosci       Date:  2014-09-26       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.